{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:40:34Z","timestamp":1791999634534,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773335 , 82003322 and 81803131"],"award-info":[{"award-number":["81773335 , 82003322 and 81803131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773335 , 82003322 and 81803131"],"award-info":[{"award-number":["81773335 , 82003322 and 81803131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773335 , 82003322 and 81803131"],"award-info":[{"award-number":["81773335 , 82003322 and 81803131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to investigate the potential biomarkers of vitiligo by evaluating the disease activity and curative effect of autologous cultured pure melanocyte transplantation (CMT) on patients. Altogether, 36patients with stable vitiligo were treated with CMT. Blister fluid samples were collected from patients with stable vitiligo. Patients with active vitiligo were matched with healthy controls. The chemokine levels in the serum and blister fluid samples were measured using Luminex. The curative effect on patients with stable vitiligo was evaluated 6\u00a0months after treatment. Treatment responses were defined according to the extent of repigmentation as effective (if 50% or more repigmentation was achieved) or ineffective (if less than 50% or worse repigmentation was achieved). Patients received re-transplantation if the initial treatment was ineffective. The levels of C-X-C motif chemokine ligand (CXCL)9 and CXCL10 in blister fluid samples were significantly lower in stable patients than in active participants. Receiver operating characteristic analysis revealed that the levels of CXCL9 and CXCL10 were sensitive and specific in diagnosing active vitiligo. Further, 65.6% (21\/32) of patients who received CMT had effective treatment responses. The high CXCL9 level in the blister fluid was a significant predictor of ineffective treatment responses. The treatment response was significantly enhanced after treatment. Four patients with ineffective treatment responses received anti-inflammatory treatment and re-transplantation. The CXCL9 and CXCL10 levels in the blister fluid were related to the presence of active vitiligo. Also, the CXCL9 level was a predictor of the effectiveness of CMT in treating vitiligo.<\/jats:p>","DOI":"10.1038\/s41598-021-97296-2","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T10:03:16Z","timestamp":1631613796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation"],"prefix":"10.1038","volume":"11","author":[{"given":"Fuquan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoni","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai\u2011E.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"97296_CR1","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine, K. et al. Revised classification\/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res. 25, E1-13 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"issue":"6","key":"97296_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/pcmr.12878","volume":"33","author":"ZA Abdel-Malek","year":"2020","unstructured":"Abdel-Malek, Z. A. et al. The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 33(6), 778\u2013787 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"97296_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.autrev.2010.02.013","volume":"9","author":"M Abu Tahir","year":"2010","unstructured":"Abu Tahir, M., Pramod, K., Ansari, S. H. & Ali, J. Current remedies for vitiligo. Autoimmun. Rev. 9, 516\u2013520 (2010).","journal-title":"Autoimmun. Rev."},{"key":"97296_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jama.293.6.730","volume":"293","author":"PE Grimes","year":"2005","unstructured":"Grimes, P. E. New insights and new therapies in vitiligo. JAMA 293, 730\u2013735 (2005).","journal-title":"JAMA"},{"key":"97296_CR5","first-page":"1","volume":"24","author":"AF Nahhas","year":"2019","unstructured":"Nahhas, A. F., Braunberger, T. L. & Hamzavi, I. H. Update on the management of vitiligo. Skin Ther. Lett. 24, 1\u20136 (2019).","journal-title":"Skin Ther. Lett."},{"key":"97296_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Taieb","year":"2013","unstructured":"Taieb, A. et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br. J. Dermatol. 168, 5\u201319 (2013).","journal-title":"Br. J. Dermatol."},{"key":"97296_CR7","first-page":"520","volume":"165","author":"WS Hong","year":"2011","unstructured":"Hong, W. S., Hu, D. N., Qian, G. P., McCormick, S. A. & Xu, A. E. Ratio of size of recipient and donor areas in treatment of vitiligo by autologous cultured melanocyte transplantation. Br. J. Dermatol. 165, 520\u2013525 (2011).","journal-title":"Br. J. Dermatol."},{"key":"97296_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1468-3083.2010.03824.x","volume":"25","author":"WS Hong","year":"2011","unstructured":"Hong, W. S., Hu, D. N., Qian, G. P., McCormick, S. A. & Xu, A. E. Treatment of vitiligo in children and adolescents by autologous cultured pure melanocytes transplantation with comparison of efficacy to results in adults. J. Eur. Acad. Dermatol. Venereol. JEADV. 25, 538\u2013543 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV."},{"key":"97296_CR9","doi-asserted-by":"publisher","first-page":"e60254","DOI":"10.1371\/journal.pone.0060254","volume":"8","author":"MN Zhou","year":"2013","unstructured":"Zhou, M. N. et al. Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8+ T cell activity, a determining factor of vitiligo patients\u2019 autologous melanocytes transplantation efficiency. PLoS ONE 8, e60254 (2013).","journal-title":"PLoS ONE"},{"key":"97296_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn, J. G. et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129, 2220\u20132232 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"97296_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4049\/jimmunol.1900027","volume":"203","author":"RL Riding","year":"2019","unstructured":"Riding, R. L. & Harris, J. E. The role of memory CD8(+) T cells in vitiligo. J. Immunol. 203, 11\u201319 (2019).","journal-title":"J. Immunol."},{"key":"97296_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.autrev.2006.03.012","volume":"5","author":"K Oyarbide-Valencia","year":"2006","unstructured":"Oyarbide-Valencia, K. et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun. Rev. 5, 486\u2013492 (2006).","journal-title":"Autoimmun. Rev."},{"key":"97296_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1078\/0171-9335-00423","volume":"83","author":"J Steitz","year":"2004","unstructured":"Steitz, J., Wenzel, J., Gaffal, E. & Tuting, T. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur. J. Cell Biol. 83, 797\u2013803 (2004).","journal-title":"Eur. J. Cell Biol."},{"key":"97296_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/pcmr.12559","volume":"30","author":"A Maouia","year":"2017","unstructured":"Maouia, A. et al. Differential expression of CXCL9, CXCL10, and IFN-gamma in vitiligo and alopecia areata patients. Pigment Cell Melanoma Res. 30, 259\u2013261 (2017).","journal-title":"Pigment Cell Melanoma Res."},{"key":"97296_CR15","doi-asserted-by":"publisher","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6, 223ra223 (2014).","journal-title":"Sci. Transl. Med."},{"key":"97296_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","volume":"16","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert, R., Speeckaert, M., De Schepper, S. & van Geel, N. Biomarkers of disease activity in vitiligo: a systematic review. Autoimmun. Rev. 16, 937\u2013945 (2017).","journal-title":"Autoimmun. Rev."},{"key":"97296_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","volume":"76","author":"JP Strassner","year":"2017","unstructured":"Strassner, J. P., Rashighi, M., Ahmed Refat, M., Richmond, J. M. & Harris, J. E. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J. Am. Acad. Dermatol. 76, 847-855.e845 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"97296_CR18","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","volume":"174","author":"XX Wang","year":"2016","unstructured":"Wang, X. X. et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br. J. Dermatol. 174, 1318\u20131326 (2016).","journal-title":"Br. J. Dermatol."},{"key":"97296_CR19","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.autrev.2017.07.006","volume":"16","author":"SM Ferrari","year":"2017","unstructured":"Ferrari, S. M. et al. Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. Autoimmun. Rev. 16, 946\u2013950 (2017).","journal-title":"Autoimmun. Rev."},{"key":"97296_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207\u2013215 (2011).","journal-title":"Immunol. Cell Biol."},{"key":"97296_CR21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris, J. E. et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869\u20131876 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"97296_CR22","first-page":"343","volume":"3","author":"M Rashighi","year":"2015","unstructured":"Rashighi, M. & Harris, J. E. Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann. Transl. Med. 3, 343 (2015).","journal-title":"Ann. Transl. Med."},{"key":"97296_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/pcmr.12667","volume":"31","author":"M Abdallah","year":"2018","unstructured":"Abdallah, M. et al. CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study. Pigment Cell Melanoma Res. 31, 330\u2013336 (2018).","journal-title":"Pigment Cell Melanoma Res."},{"key":"97296_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin, D. et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 396, 110\u2013120 (2020).","journal-title":"Lancet"},{"key":"97296_CR25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein, B. et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J. Am. Acad. Dermatol. 76, 1054-1060e1051 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"97296_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2003.12.013","volume":"51","author":"YF Chen","year":"2004","unstructured":"Chen, Y. F. et al. Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J. Am. Acad. Dermatol. 51, 68\u201374 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"97296_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/1523-1747.ep12470973","volume":"89","author":"AB Lerner","year":"1987","unstructured":"Lerner, A. B., Halaban, R., Klaus, S. N. & Moellmann, G. E. Transplantation of human melanocytes. J. Invest. Dermatol. 89, 219\u2013224 (1987).","journal-title":"J. Invest. Dermatol."},{"key":"97296_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2340\/00015555734951","volume":"73","author":"MJ Olsson","year":"1993","unstructured":"Olsson, M. J. & Juhlin, L. Repigmentation of vitiligo by transplantation of cultured autologous melanocytes. Acta Derm. Venereol. 73, 49\u201351 (1993).","journal-title":"Acta Derm. Venereol."},{"key":"97296_CR29","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/j.1365-2133.2008.08521.x","volume":"158","author":"P Redondo","year":"2008","unstructured":"Redondo, P., del Olmo, J., Garcia-Guzman, M., Guembe, L. & Prosper, F. Repigmentation of vitiligo by transplantation of autologous melanocyte cells cultured on amniotic membrane. Br. J. Dermatol. 158, 1168\u20131171 (2008).","journal-title":"Br. J. Dermatol."},{"key":"97296_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/pcmr.12086","volume":"26","author":"YL Shi","year":"2013","unstructured":"Shi, Y. L. et al. MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo. Pigment Cell Melanoma Res. 26, 418\u2013421 (2013).","journal-title":"Pigment Cell Melanoma Res."},{"key":"97296_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond, J. M. et al. Keratinocyte-derived chemokines orchestrate t-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest. Dermatol. 137, 350\u2013358 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"97296_CR32","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jid.2017.12.021","volume":"138","author":"P Kuo","year":"2018","unstructured":"Kuo, P. et al. HPV16E7-induced hyperplasia promotes CXCL9\/10 expression and induces CXCR3(+) T-cell migration to skin. J. Invest. Dermatol. 138, 1348\u20131359 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"97296_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.immuni.2012.11.012","volume":"38","author":"W Kastenmuller","year":"2013","unstructured":"Kastenmuller, W. et al. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. Immunity 38, 502\u2013513 (2013).","journal-title":"Immunity"},{"key":"97296_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/lsm.23198","volume":"52","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Multi-factors associated with efficacy and adverse events of fractional erbium:YAG laser-assisted delivery of topical betamethasone for stable vitiligo: a retrospective analysis. Lasers Surg. Med. 52, 590\u2013596 (2020).","journal-title":"Lasers Surg. Med."},{"key":"97296_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/jocd.12704","volume":"18","author":"ZA Ibrahim","year":"2019","unstructured":"Ibrahim, Z. A., Hassan, G. F., Elgendy, H. Y. & Al-Shenawy, H. A. Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo. J. Cosmet. Dermatol. 18, 581\u2013588 (2019).","journal-title":"J. Cosmet. Dermatol."},{"key":"97296_CR36","first-page":"999","volume":"37","author":"J Li","year":"2011","unstructured":"Li, J. et al. Suction blister epidermal grafting using a modified suction method in the treatment of stable vitiligo: a retrospective study. Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. 37, 999\u20131006 (2011).","journal-title":"Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg."},{"key":"97296_CR37","first-page":"702","volume":"26","author":"HU Kim","year":"2000","unstructured":"Kim, H. U. & Yun, S. K. Suction device for epidermal grafting in vitiligo: employing a syringe and a manometer to provide an adequate negative pressure. Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. 26, 702\u2013704 (2000).","journal-title":"Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97296-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T19:43:31Z","timestamp":1699472611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97296-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97296"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97296-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18298"}}